Cargando…

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected

Detalles Bibliográficos
Autores principales:	Atreya, Raja, Neurath, Markus F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777001/ https://www.ncbi.nlm.nih.gov/pubmed/34740616 http://dx.doi.org/10.1016/j.jcmgh.2021.10.003

Ejemplares similares

Expect the Unexpected!
por: Zimmerman, Karen G., et al.
Publicado: (2021)

Kruppel-like Factor 14 as Driver of Regulatory T-Cell Activity in Intestinal Inflammation
por: Neurath, Markus F.
Publicado: (2015)

The Ratio of Observed to Expected: How Much of It Is Unexpected?
por: Chapman, Jens R., et al.
Publicado: (2018)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
por: Wang, Bo, et al.
Publicado: (2020)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
por: Lee, Ji Sang, et al.
Publicado: (2019)

Expecting the unexpected
Publicado: (1995)

Expect the unexpected
por: Rathee, Manu
Publicado: (2014)

Tofacitinib as a Promising Therapeutic Option in Refractory Autoimmune-Mediated Vascular and Sclera Inflammation
por: Dimitroulas, Theodoros
Publicado: (2023)

Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics
por: Texler, Bernhard, et al.
Publicado: (2021)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Expected and Unexpected Effects of Vaccination
por: Martinon-Torres, Federico
Publicado: (2017)

Commentary: Expecting the unexpected
por: Akhmerov, Akbarshakh, et al.
Publicado: (2021)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
por: Lee, Ji-Sang, et al.
Publicado: (2021)

Use of Tofacitinib in the Management of COVID-19 Pneumonia
por: Bande, Balasaheb D
Publicado: (2021)

CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-γ Producing Innate Lymphoid CelIs and Protects From Experimental Colitis
por: Kang, Le, et al.
Publicado: (2021)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease
por: Klenske, Entcho, et al.
Publicado: (2019)

Interplay of GTPases and Cytoskeleton in Cellular Barrier Defects during Gut Inflammation
por: López-Posadas, Rocío, et al.
Publicado: (2017)

Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
por: Monteleone, Giovanni, et al.
Publicado: (2022)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
por: Atreya, Imke, et al.
Publicado: (2022)

Expected and Unexpected Effects of Pharmacological Antioxidants
por: Tyuryaeva, Irina, et al.
Publicado: (2023)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Redundant publication: Expect the unexpected
por: Kannan, S., et al.
Publicado: (2014)

Wilson’s Disease: Expect the Unexpected
por: El Imad, Talal, et al.
Publicado: (2018)

Necrotizing Fasciitis: Expect the unexpected
por: Khalid, Maha, et al.
Publicado: (2020)

Quiet Brainstorming: Expecting the Unexpected
por: Prominski, Aleksander, et al.
Publicado: (2020)

Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2019)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers
por: Menon, Sujatha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_41al1pqotra7hpuh3eirafjumk